Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
14.03
+0.58 (4.31%)
Aug 14, 2025, 12:04 PM - Market open
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 270 employees as of December 31, 2024. The number of employees increased by 86 or 46.74% compared to the previous year.
Employees
270
Change (1Y)
86
Growth (1Y)
46.74%
Revenue / Employee
$288,641
Profits / Employee
-$1,240,696
Market Cap
1.21B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 270 | 86 | 46.74% |
| Dec 31, 2023 | 184 | 77 | 71.96% |
| Dec 31, 2022 | 107 | 48 | 81.36% |
| Dec 31, 2021 | 59 | 16 | 37.21% |
| Dec 31, 2020 | 43 | 8 | 22.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNDX News
- 17 hours ago - Syndax Pharmaceuticals: A Tale Of Two Drug Launches - Seeking Alpha
- 7 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Syndax Pharmaceuticals: The Story Brightens - Seeking Alpha
- 9 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 - GlobeNewsWire
- 5 weeks ago - Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals - Seeking Alpha
- 7 weeks ago - Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - GlobeNewsWire